Drugs / Sargramostim (GM-CSF)
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| — | NCT00665002 Background | Jun 2008 → Jul 2013 | leukemia | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sargramostim (GM-CSF) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00665002 ↗ |
| Route | Subcutaneous | “GM-CSF was administered at a dose 70 mcg (140ul) as a subcutaneous injection at the site of vaccination on day -2 and day 0.” NCT00665002 ↗ |